NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors Leave a reply CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, part of the M42 group —

NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors Leave a reply CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, part of the M42 group —

NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors Leave a reply CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, part of the M42 group —

NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors Leave a reply CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, part of the M42 group —

NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors Leave a reply CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, part of the M42 group —

CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expansion into the Middle East. Its wholly owned subsidiary, NuroMENA Holdings Ltd., has signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, part of the M42 group — a global health company powered by Artificial Intelligence (AI), technology and genomics. In a concurrent strategic move, NeOnc is

Over the next three years, an estimated 60,000 screenings and 6,000 cataract surgeries will be performed, offering thousands the chance to regain their sight—and with it, renewed opportunities for work and a better quality of life Advancing Sustainable Outcomes, the multi-year project will Strengthen Ophthalmic Capacity in Sierra Leone through Ministry of Health Collaboration Over 1,500 cataract surgeries have been carried out in the initiative’s first year—delivering vital eye care to some of Sierra Leone’s most underserved communities, helping restore vision and dignity where it’s needed most DUBAI , UAE – EQS Newswire – 9 October 2025 – In a concerted

تعزيز النتائج المستدامة؛ سيعزّز المشروع عبر سنواته المتعدّدة قدرات مجال طب العيون في دولة سيراليون من خلال التعاون مع وزارة الصحة لقد تم إجراء أكثر من 1500 عملية جراحية لإزالة المياه البيضاء في العام الأول من المبادرة، ممّا أدى إلى تقديم الرعاية الحيوية للعيون في بعض المجتمعات الأكثر حرمانًا في دولة سيراليون، كما ساعد ذلك على استعادة البصر والكرامة حيث تشتد الحاجة إليهما. في إطار الجهود المتضافرة للحد من العمى الذي يمكن تجنّبه، شرعت مؤسّستا شويترامس الدولية ونور دبي (عضو مبادرات محمد بن راشد آل مكتوم العالمية)، بالتنسيق مع وزارة الصحة في دولة سيراليون، في برنامج شامل للتوعية بمرض المياه